{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:24:59Z","timestamp":1787865899846,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12149-025-02139-z","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:23:48Z","timestamp":1764908628000},"page":"384-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-5747","authenticated-orcid":false,"given":"Felix","family":"Kind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Nemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula A.","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2139_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"2139_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus Cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"key":"2139_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"2139_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic Castration-Resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63:1651\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","journal-title":"J Nucl Med"},{"key":"2139_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet Elsevier. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet Elsevier"},{"key":"2139_CR6","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/j.ijrobp.2024.07.1209","volume":"120","author":"H Kim","year":"2024","unstructured":"Kim H, Tagawa ST, Sartor AO, Saad F, Reid A, Sakharova O, et al. PSMAddition: phase 3 trial of [177lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic Hormone-Sensitive prostate cancer. Int J Radiation Oncol Biology Phys Elsevier. 2024;120:e546. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.1209.","journal-title":"Int J Radiation Oncol Biology Phys Elsevier"},{"key":"2139_CR7","unstructured":"U.S. Food and Drug Administration. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) \u2014 Prescribing Information. Silver Spring, MD: FDA; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215833s021s024lbl.pdf Accessed November 14, 2025."},{"key":"2139_CR8","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2139_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/RLU.0000000000002575","volume":"44","author":"J Wang","year":"2019","unstructured":"Wang J, Zang J, Wang H, Liu Q, Li F, Lin Y, et al. Pretherapeutic 68Ga-PSMA-617 PET May indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in main organs and tumor lesions. Clin Nucl Med. 2019;44:431\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000002575.","journal-title":"Clin Nucl Med"},{"key":"2139_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, Hofferber R, Priv\u00e9 BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49:1101\u201312. https:\/\/doi.org\/10.1007\/s00259-021-05538-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2139_CR11","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, H\u00fcttmann T, Seitz AK, K\u00fcbler H, Serfling SE, Schl\u00f6telburg W, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50:3465\u201374. https:\/\/doi.org\/10.1007\/s00259-023-06281-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2139_CR12","doi-asserted-by":"publisher","first-page":"1234853","DOI":"10.3389\/fnume.2023.1234853","volume":"3","author":"R Gutsche","year":"2023","unstructured":"Gutsche R, G\u00fclm\u00fcs G, Mottaghy FM, G\u00e4rtner F, Essler M, von Mallek D, et al. Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Front Nucl Med. 2023;3:1234853. https:\/\/doi.org\/10.3389\/fnume.2023.1234853.","journal-title":"Front Nucl Med"},{"key":"2139_CR13","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert R, Seitzer K, Herrmann K, Kessel K, Sch\u00e4fers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812\u201320. https:\/\/doi.org\/10.7150\/thno.47251.","journal-title":"Theranostics"},{"key":"2139_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12094-024-03625-y","volume":"27","author":"I Henr\u00edquez","year":"2025","unstructured":"Henr\u00edquez I, Malave B, Campos FL, Hidalgo EC, Muelas R, Ferrer C, et al. PSMA PET\/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC). Clin Transl Oncol. 2025;27:706\u201315. https:\/\/doi.org\/10.1007\/s12094-024-03625-y.","journal-title":"Clin Transl Oncol"},{"key":"2139_CR15","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2139_CR16","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl F-X, Buck AK, Rowe SP, Higuchi T, Seitz AK, et al. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3269\u201376. https:\/\/doi.org\/10.1007\/s00259-022-05744-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2139_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"2139_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T, Spielhofer N, Skawran S, Heimer J, et al. Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res. 2024;14:36. https:\/\/doi.org\/10.1186\/s13550-024-01097-3.","journal-title":"EJNMMI Res"},{"key":"2139_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-Head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527\u201332. https:\/\/doi.org\/10.2967\/jnumed.119.234187.","journal-title":"J Nucl Med"},{"key":"2139_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11548-013-0840-8","volume":"8","author":"M Nolden","year":"2013","unstructured":"Nolden M, Zelzer S, Seitel A, Wald D, M\u00fcller M, Franz AM, et al. The medical imaging interaction toolkit: challenges and advances: 10 years of open-source development. Int J Comput Assist Radiol Surg. 2013;8:607\u201320. https:\/\/doi.org\/10.1007\/s11548-013-0840-8.","journal-title":"Int J Comput Assist Radiol Surg"},{"key":"2139_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ijrobp.2018.05.053","volume":"102","author":"A Traverso","year":"2018","unstructured":"Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: A systematic review. Int J Radiat Oncol Biol Phys. 2018;102:1143\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2139_CR22","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3109\/0284186X.2013.812798","volume":"52","author":"RTH Leijenaar","year":"2013","unstructured":"Leijenaar RTH, Carvalho S, Velazquez ER, van Elmpt WJC, Parmar C, Hoekstra OS, et al. Stability of FDG-PET radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol. 2013;52:1391\u20137. https:\/\/doi.org\/10.3109\/0284186X.2013.812798.","journal-title":"Acta Oncol"},{"key":"2139_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2967\/jnumed.116.184655","volume":"58","author":"M Hatt","year":"2017","unstructured":"Hatt M, Tixier F, Visvikis D, Le Cheze C. Radiomics in PET\/CT: more than Meets the eye? J Nucl Med. 2017;58:365\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.184655.","journal-title":"J Nucl Med"},{"key":"2139_CR24","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for Castration-Resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"2139_CR25","doi-asserted-by":"crossref","first-page":"P1619","DOI":"10.2967\/jnumed.123.265509","volume":"64","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler W, Hadaschik B, Herrmann K, et al. Practical RECIP: visual assessment of response evaluation criteria in PSMA-PET\/CT in metastatic castration-resistant prostate cancer. J Nuclear Med Soc Nuclear Med. 2023;64:P1619\u20131619.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"2139_CR26","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. https:\/\/doi.org\/10.1136\/bmj.g7594.","journal-title":"BMJ"},{"key":"2139_CR27","unstructured":"Crack TF. Foundations for Scientific Investing: Capital Markets Intuition and Critical Thinking Skills. 11th ed. 2022."},{"key":"2139_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, H\u00fcsing J, Claassen K, M\u00f6ller L, Kaj\u00fcter H, Oesterling F, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25:1188\u2013201. https:\/\/doi.org\/10.1016\/S1470-2045(24)00326-7.","journal-title":"Lancet Oncol"},{"key":"2139_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02139-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:36:33Z","timestamp":1774686993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02139-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2139"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02139-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present retrospective study was conducted in accordance with the guidelines of the Declaration of Helsinki (Washington, World Medical Association, 2013) and was approved by the ethics committee of the University of Freiburg (Vote no. 24-1056).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the presented data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}